Tom Stribling has a 30 year record in the health industry. Companies he led have traditionally reached successful and profitable liquidity through sale to larger corporations. Prior to the current venture he started three other companies; one as a new division of a major chemical corp.; a second at the request of a leading VC firm and another that he conceived, privately funded, grew and sold to a major foreign corp. in less than four years.

Dr. Lam is Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, and is an Assistant Professor in the Department of Pediatrics, Division of hematology/Oncology at Emory University School of Medicine. He leads an interdisciplinary laboratory based at Georgia Tech and Emory dedicate to developing new diagnostic techniques for hematologic and childhood disorders.

Ms. Tyburski began working on AnemoCheck in her senior year of undergraduate school at the Georgia Institute of Technology. After graduating with a bachelor's of science in Biomedical Engineering from Tech in 2012, she joined Dr. Wilbur Lam's laboratory based at Emory and Georgia Tech and continues to conduct prototype development, interference and stability studies and clinical assessments on the product.

Dr. Lyon is Professor of Chemistry and Dean of the Schmid College of Science and Technology at Chapman University in Orange, CA, and is an analytical/materials/physical chemist who has developed new bioanalytical tools for ~17 years. He has extensive experience in redox chemistry and dye-mediated electron transfer systems such as those utilized in AnemoCheck, which he helped characterize and optimize

Tom Stribling has a 30 year record in the health industry. Companies he led have traditionally reached successful and profitable liquidity through sale to larger corporations. Prior to the current venture he started three other companies; one as a new division of a major chemical corp.; a second at the request of a leading VC firm and another that he conceived, privately funded, grew and sold to a major foreign corp. in less than four years.